TRENTON, N.J. (AP) – Federal regulators have approved the first non-opioid treatment to ease withdrawal symptoms from quitting addictive opioids.
The U.S. Food and Drug Administration expedited approval of Lucemyra to help combat the U.S. opioid epidemic.READ MORE: Truck Loses Control, Slams Into Royse City Police Officer Michael Baley While Helping Stranded Motorist
The tablet was approved Wednesday to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction treatment but can be part of a longer-term plan.READ MORE: Customs Officers Seize Narcotics At Texas-Mexico Border Worth $1.8M+ Hidden In Tires, Ice Chests
People going through detox are usually given opioid medicine like methadone, which eases the cravings without an intense high. Fear of withdrawal discourages some people from quitting.
The FDA is requiring drugmaker US WorldMeds of Louisville, Kentucky, to conduct safety studies in teens and newborns of opioid-addicted mothers and for possible longer-term use in people tapering off opioids.MORE NEWS: Man Wanted In Dallas For Child Sexual Assault Charges, Jose Gerardo Ibarra Arrested At U.S.-Mexico Border
(© Copyright 2018 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.)